EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Optimizing target inactivation to treat multidrug-resistant Escherichia coli with NDM and PBP3 mutations: “going the extra mile”

Claudia Fabrizio iD, Felice Valzano iD, Simone Giuliano, Elisabetta Morelli, Daniela Serio, Giovanni Battista Buccoliero, Maurizio Cervellera, Gianfranco La Bella, Fabio Arena, Andrea M Hujer iD, Magdalena A Taracila, Steven H Marshall und 2 weitere

Antimicrobial Agents and Chemotherapy · 2026

DOI: 10.1128/aac.00887-25 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2026. Verfasst von Claudia Fabrizio und 13 weiteren Autor:innen. Beteiligte Einrichtung: Infectious and Tropical Diseases Clinic, San Giuseppe Moscati Hospital, Taranto, Italy. Hauptthemen laut MEDLINE: Escherichia coli, Drug Resistance, Multiple, Bacterial, beta-Lactamases, Anti-Bacterial Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A 65-year-old man without identifiable risk factors for multidrug-resistant pathogens was admitted with peritonitis, isolating NDM-producing Escherichia coli from a rectal swab and intraoperative samples. After surgery, ceftazidime-avibactam/aztreonam was administered. Due to poor clinical response, he was switched to imipenem-relebactam/aztreonam, resulting in a successful outcome. Whole-genome sequencing detected bla NDM-5 and bla CMY-148 β-lactamases, PBP3 YRIN insertion, and mutated cirA gene. This case illustrates the importance of considering different mechanisms of resistance when choosing combination therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Escherichia coliDrug Resistance, Multiple, Bacterialbeta-LactamasesAnti-Bacterial AgentsPenicillin-Binding ProteinsEscherichia coli InfectionsHumansImipenemCeftazidimeAgedMaleAzabicyclo CompoundsMutationAztreonamMicrobial Sensitivity TestsDrug CombinationsEscherichia coli Proteins

Stichwörter der Autor:innen

CMYE. coliNDM-5aztreonamdouble β-lactam combinationsimipenem/relebactampenicillin binding protein3

Substanzen

beta-LactamasesAnti-Bacterial AgentsImipenemCeftazidimeAzabicyclo CompoundsAztreonamPenicillin-Binding ProteinsDrug Combinationsavibactam, ceftazidime drug combinationEscherichia coli Proteins

Autor:innen und Institutionen

  • Infectious and Tropical Diseases Clinic, San Giuseppe Moscati Hospital, Taranto, Italy.
  • Department of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy.
  • Infectious Diseases Clinic, Department of Medicine (DMED), University of Udine, Udine, Italy.
  • Clinical Pathology Unit, SS Annunziata Hospital, Taranto, Italy.
  • Intensive Care Unit, SS Annunziata Hospital, Taranto, Italy.
  • General Surgery Unit, SS Annunziata Hospital, Taranto, Italy.

ORCID-Profile: Claudia Fabrizio, Felice Valzano, Andrea M Hujer, Robert A Bonomo, Carlo Tascini

Zitieren

APA

Fabrizio, C., Valzano, F., Giuliano, S., Morelli, E., Serio, D., Buccoliero, G. B., Cervellera, M., La Bella, G., Arena, F., Hujer, A. M., Taracila, M. A., Marshall, S. H., Bonomo, R. A., & Tascini, C. (2026). Optimizing target inactivation to treat multidrug-resistant Escherichia coli with NDM and PBP3 mutations: “going the extra mile”. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00887-25

Vancouver

Fabrizio C, Valzano F, Giuliano S, Morelli E, Serio D, Buccoliero GB, et al. Optimizing target inactivation to treat multidrug-resistant Escherichia coli with NDM and PBP3 mutations: “going the extra mile”. Antimicrobial Agents and Chemotherapy. 2026. doi:10.1128/aac.00887-25

BibTeX
@article{Fabrizio2026,
  author = {Fabrizio, Claudia and Valzano, Felice and Giuliano, Simone and Morelli, Elisabetta and Serio, Daniela and Buccoliero, Giovanni Battista and Cervellera, Maurizio and La Bella, Gianfranco and Arena, Fabio and Hujer, Andrea M and Taracila, Magdalena A and Marshall, Steven H and Bonomo, Robert A and Tascini, Carlo},
  title = {Optimizing target inactivation to treat multidrug-resistant Escherichia coli with NDM and PBP3 mutations: “going the extra mile”},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2026},
  doi = {10.1128/aac.00887-25}
}
Kostenlos starten →